Back Dictionary Export CSV
Filter: Clear
MERGED_REGIMEN_ID MERGED_TUMOUR_ID HEIGHT_AT_START_OF_REGIMEN WEIGHT_AT_START_OF_REGIMEN INTENT_OF_TREATMENT DATE_DECISION_TO_TREAT START_DATE_OF_REGIMEN MAPPED_REGIMEN CLINICAL_TRIAL CHEMO_RADIATION MERGED_PATIENT_ID BENCHMARK_GROUP
220020680 220017654 1.72 81 Curative (C) 2017-11-21 2017-11-21 ALEMTUZUMAB + FLUDARABINE + MELPHALAN 02 N 220028304 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020681 220007343 1.82 null Curative (C) 2015-07-12 2015-07-12 Dasatinib N N 220028308 DASATINIB
220020682 220007347 1.66 63.5 Disease modification (D) 2013-04-27 2013-12-07 Dasatinib 01 N 220028341 DASATINIB
220020683 220007350 1.7 null null 2015-10-29 2015-10-29 Dasatinib 99 N 220028355 DASATINIB
220020684 220017661 1.71 0 Curative (C) 2019-06-16 2019-06-17 Rituximab N N 220028388 RITUXIMAB
220020685 220014056 0 44.7 Disease modification (D) 2016-02-02 2016-02-02 ALEMTUZUMAB + FLUDARABINE + MELPHALAN 2 N 220028395 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020686 220007362 1.78 108 Curative (C) 2014-10-24 2014-10-24 ALEMTUZUMAB + FLUDARABINE + MELPHALAN N N 220028396 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020687 220021883 1.74 90 Curative (C) null 2017-03-20 AML18 PILOT TRIAL null N 220028429 PILOT TRIAL
220020688 220007379 null 77.7 Disease modification (D) 2013-11-25 2014-02-13 Alemtuz+Fludara+Melphalan RIC MUD 02 N 220028490 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020689 220007385 null 59.4 Curative (C) 2015-03-05 2015-04-05 ALEMTUZUMAB + FLUDARABINE + MELPHALAN null N 220028504 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020690 220007390 1.8 90 Curative (C) 2016-04-27 2016-04-27 Rituximab N N 220028517 RITUXIMAB
220020691 220007398 1.63 87 Curative (C) 2017-04-21 2017-06-10 AML18 PILOT TRIAL Y N 220028542 PILOT TRIAL
220020692 220007419 1.81 83.7 Disease modification (D) 2017-12-06 2017-12-06 Rituximab N N 220028662 RITUXIMAB
220020693 220014088 1.67 50.4 null 2016-08-05 2016-08-06 ALEMTUZUMAB + FLUDARABINE + MELPHALAN N N 220028681 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020694 220007425 1.8 null Curative (C) 2013-11-24 2014-10-14 Dasatinib N N 220028684 DASATINIB
220020695 220007431 1.49 0 Curative (C) null 2014-11-12 AML18 PILOT TRIAL 01 null 220028709 PILOT TRIAL
220020696 220007443 1.79 72 Curative (C) 2017-08-28 2017-09-01 AML 18 TRIAL 01 N 220028763 AML18 TRIAL
220020697 220021885 1.67 78.4 Disease modification (D) 2014-10-09 2014-10-16 ALEMTUZUMAB + FLUDARABINE + MELPHALAN 2 N 220028778 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020698 220007452 null null Disease modification (D) 2013-07-18 2013-08-25 Rituximab N N 220028801 RITUXIMAB
220020699 220007458 1.72 89.4 Curative (C) 2018-05-29 2018-05-29 AML 18 Pilot Trial N Y 220028807 PILOT TRIAL
220020700 220014106 1.56 62.9 Palliative (P) 2018-02-07 2018-04-18 AML 18 TRIAL 01 N 220028812 AML18 TRIAL
220020701 220007472 1.65 95.2 null 2016-03-25 2016-03-25 Rituximab 99 N 220028868 RITUXIMAB
220020702 220007479 1.78 67.2 Curative (C) 2016-01-05 2016-06-17 AML18 PILOT TRIAL N N 220028892 PILOT TRIAL
220020703 220007483 1.5 0 Disease modification (D) 2016-06-10 2016-06-14 Dasatinib N N 220028901 DASATINIB
220020705 220007510 null 90 Curative (C) 2015-02-23 2015-02-23 Alemtuz+Fludara+Melphalan RIC MUD 02 N 220028990 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020706 220007516 1.52 81 Curative (C) 2015-05-08 2015-06-10 AML18 PILOT TRIAL 02 N 220028997 PILOT TRIAL
220020707 220007517 1.6 44.3 Curative (C) 2018-02-07 2018-03-25 AML 18 TRIAL Y N 220028999 AML18 TRIAL
220020708 220007529 null null null 2018-06-02 2018-06-05 Rituximab N null 220029043 RITUXIMAB
220020710 220007548 1.78 72.7 Curative (C) 2018-04-21 2018-04-26 AML18 PILOT TRIAL N N 220029118 PILOT TRIAL
220020711 220007551 1.79 80.7 Curative (C) 2014-07-19 2014-09-04 AML 18 TRIAL Y N 220029122 AML18 TRIAL
220020713 220007555 1.61 57.2 Curative (C) 2015-12-24 2016-01-10 Alemtuz+Fludara+Melphalan RIC MUD N N 220029134 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020715 220007579 0 80.9 Curative (C) 2019-07-15 2019-10-18 Alemtuz+Fludara+Melphalan RIC MUD N N 220029242 ALEMTUZUMAB + FLUDARABINE + MELPHALAN
220020716 220007583 1.58 71.9 null 2017-08-17 2017-08-20 AML 18 TRIAL null N 220029268 AML18 TRIAL
220020717 220007584 1.74 65 Curative (C) 2016-01-06 2016-01-06 ATG + Busulfan + Fludarabine 02 N 220029273 ATG + BUSULFAN + FLUDARABINE
220020718 220007588 1.65 84.6 Curative (C) null 2018-06-12 CYCLOPHOSPHAMIDE + FLUDARABINE null N 220029292 CYCLOPHOSPHAMIDE + FLUDARABINE
220020719 220007595 1.7 68.2 Curative (C) 2019-02-27 2019-03-02 CYCLOPHOSPHAMIDE + FLUDARABINE N N 220029327 CYCLOPHOSPHAMIDE + FLUDARABINE
220020721 220014197 1.73 147 Curative (C) 2014-07-04 2014-07-11 AML16 DA 2+5 null N 220029445 AML16 TRIAL
220020722 220007636 1.43 68.8 Curative (C) null 2017-04-02 BOSUTINIB Y null 220029467 BOSUTINIB
220020723 220007639 1.6 79.4 Curative (C) 2015-10-12 2015-11-20 RUXOLITINIB N N 220029470 RUXOLITINIB
220020724 220007652 1.55 60 Palliative (P) 2014-01-27 2014-02-03 RUXOLITINIB N N 220029514 RUXOLITINIB
220020725 220019739 1.68 61.2 Curative (C) 2016-08-06 2016-08-06 FLAG N N 220029559 FLAG
220020726 220017759 null 60 Curative (C) 2014-07-28 2014-07-31 Cyclophosphamide TBI Allograft N null 220029586 CYCLOPHOSPHAMIDE
220020727 220007667 1.63 14 Curative (C) 2016-11-19 2016-11-19 Idarubicin+Tretinoin Spanish Crse4 null null 220029599 IDARUBICIN + TRETINOIN
220020728 220007672 null 70.2 Curative (C) 2017-11-16 2017-11-21 BOSUTINIB 99 null 220029606 BOSUTINIB
220020729 220007673 null 70.8 Curative (C) 2018-01-03 2018-01-23 Idarubicin+Tretinoin Spanish Crse4 2 null 220029608 IDARUBICIN + TRETINOIN
220020730 220007680 null 60.5 Curative (C) null 2018-07-17 RUXOLITINIB N N 220029630 RUXOLITINIB
220020731 220007691 0 null Palliative (P) 2013-11-27 2013-12-02 Triple Intrathecal 2 N 220029667 TRIPLE INTRATHECAL
220020732 220007693 1.58 80.9 Curative (C) null 2015-01-10 CYCLOPHOSPHAMIDE 02 N 220029672 CYCLOPHOSPHAMIDE
220020733 220007706 null 54.4 Disease modification (D) 2016-11-21 2017-04-06 IDARUBICIN + TRETINOIN 99 N 220029704 IDARUBICIN + TRETINOIN
220020734 220007716 null 60.3 Curative (C) 2017-11-25 2018-01-13 AML16 DA 3+10 99 null 220029746 AML16 TRIAL